PMID- 29595540
OWN - NLM
STAT- MEDLINE
DCOM- 20190801
LR  - 20210223
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 29
IP  - 6
DP  - 2018 Sep
TI  - Sex-specific differences in cannabinoid-induced extracellular-signal-regulated 
      kinase phosphorylation in the cingulate cortex, prefrontal cortex, and nucleus 
      accumbens of Lister Hooded rats.
PG  - 473-481
LID - 10.1097/FBP.0000000000000395 [doi]
AB  - Sex-dependent differences have been consistently described in cannabinoid 
      addiction research. In particular, we recently reported that female Lister Hooded 
      rats display greater self-administration of the cannabinoid CB1 receptor agonist 
      WIN55,212-2 (WIN) and stronger reinstatement of cannabinoid-seeking behavior than 
      males. Cannabinoids modulate the phosphorylation of the 
      extracellular-signal-regulated kinase (ERK) pathway, leading to various forms of 
      plasticity-related learning that likely affect operant behavior. However, whether 
      or not the reported sex-dependent differences in cannabinoid-taking and 
      cannabinoid-seeking behaviors may be related to a sexual dimorphic activation of 
      the ERK pathway remains still to be determined. In the present study, we measured 
      the level of phosphoERK-positive cells in the cingulate cortex (CG1), prefrontal 
      cortex (PFCx), and nucleus accumbens of male and of intact (i.e. sham-operated) 
      and ovariectomized female Lister Hooded rats 30 and 60 min after an acute, 
      intravenous, injection of a dose of WIN (0.3 mg/kg) resembling the mean amount of 
      drug daily self-administered by trained rats. We found that WIN significantly 
      increased ERK activation in the CG1, PFCx, and nucleus accumbens in a sex time 
      and, restricted to the cortical areas, layer-specific manner. Moreover, the 
      comparison between intact and ovariectomized female rats revealed a significant 
      role played by estrogens in WIN-elicited ERK activation. These results indicate, 
      for the first time, the existence of a sexually dimorphic cannabinoid 
      receptor-dependent ERK activation that, restricted to the CG1 and PFCx, is 
      ovarian hormone-dependent.
FAU - Rosas, Michela
AU  - Rosas M
AD  - Department of Life and Environmental Sciences, Pharmaceutical, Pharmacological 
      and Nutraceutical Sciences Section.
FAU - Porru, Simona
AU  - Porru S
AD  - Department of Life and Environmental Sciences, Pharmaceutical, Pharmacological 
      and Nutraceutical Sciences Section.
FAU - Giugliano, Valentina
AU  - Giugliano V
AD  - Department of Biomedical Sciences, Division of Neuroscience and Clinical 
      Pharmacology.
FAU - Antinori, Silvia
AU  - Antinori S
AD  - Department of Biomedical Sciences, Division of Neuroscience and Clinical 
      Pharmacology.
FAU - Scheggi, Simona
AU  - Scheggi S
AD  - Department of Molecular and Developmental Medicine, University of Siena, Siena, 
      Italy.
FAU - Fadda, Paola
AU  - Fadda P
AD  - Department of Biomedical Sciences, Division of Neuroscience and Clinical 
      Pharmacology.
AD  - Department of Biomedical Sciences, Centre of Excellence 'Neurobiology of 
      Addiction', University of Cagliari.
FAU - Fratta, Walter
AU  - Fratta W
AD  - Department of Biomedical Sciences, Division of Neuroscience and Clinical 
      Pharmacology.
AD  - Department of Biomedical Sciences, Centre of Excellence 'Neurobiology of 
      Addiction', University of Cagliari.
FAU - Acquas, Elio
AU  - Acquas E
AD  - Department of Life and Environmental Sciences, Pharmaceutical, Pharmacological 
      and Nutraceutical Sciences Section.
AD  - Department of Biomedical Sciences, Centre of Excellence 'Neurobiology of 
      Addiction', University of Cagliari.
FAU - Fattore, Liana
AU  - Fattore L
AD  - Department of Biomedical Sciences, Centre of Excellence 'Neurobiology of 
      Addiction', University of Cagliari.
AD  - CNR Institute of Neuroscience - Cagliari, National Research Council, Cagliari.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Analgesics)
RN  - 0 (Benzoxazines)
RN  - 0 (Cannabinoids)
RN  - 0 (Morpholines)
RN  - 0 (Naphthalenes)
RN  - 5H31GI9502 
      ((3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
MH  - Analgesics/therapeutic use
MH  - Analysis of Variance
MH  - Animals
MH  - Benzoxazines/pharmacology
MH  - Brain/anatomy & histology/*drug effects/*enzymology
MH  - Cannabinoids/*pharmacology
MH  - Extracellular Signal-Regulated MAP Kinases/*metabolism
MH  - Female
MH  - Gyrus Cinguli/drug effects
MH  - Male
MH  - Morpholines/pharmacology
MH  - Naphthalenes/pharmacology
MH  - Nucleus Accumbens/drug effects
MH  - Ovariectomy
MH  - Phosphorylation/drug effects
MH  - Prefrontal Cortex/drug effects
MH  - Rats
MH  - *Sex Characteristics
EDAT- 2018/03/30 06:00
MHDA- 2019/08/02 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2019/08/02 06:00 [medline]
PHST- 2018/03/30 06:00 [entrez]
AID - 10.1097/FBP.0000000000000395 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2018 Sep;29(6):473-481. doi: 10.1097/FBP.0000000000000395.